What are the common gynecologic tumor markers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Gynecologic Tumor Markers

The most clinically important gynecologic tumor markers are CA-125 for epithelial ovarian cancer, beta-hCG and AFP for germ cell tumors, and inhibin for sex cord-stromal tumors, with HE4 emerging as a valuable adjunct to CA-125 in ovarian malignancies. 1, 2

Ovarian Cancer Markers

Epithelial Ovarian Tumors

  • CA-125 is the primary marker for epithelial ovarian cancer, elevated in approximately 80% of patients with stage II or greater disease, but only 50% of stage I cases 1
  • CA-125 has high correlation with clinical course during chemotherapy and can predict tumor recurrence in clinically tumor-free patients 1
  • HE4 (Human Epididymis Protein 4) combined with CA-125 improves sensitivity and specificity, particularly for early-stage detection 1, 2
  • CA 19-9 and CEA can be elevated in epithelial ovarian neoplasms; a high CA-125/CEA ratio optimizes specificity for ovarian versus gastrointestinal primary tumors 1

Important caveat: CA-125 has limited specificity—false positives occur with endometriosis, benign ovarian cysts, pregnancy, pelvic inflammatory disease, pancreatic cancer, and cirrhosis 1

Germ Cell Tumors

  • Alpha-fetoprotein (AFP) is produced by yolk sac tumors, embryonal carcinomas, polyembryomas, and immature teratomas 1, 3, 4
  • Beta-hCG (human chorionic gonadotropin) is produced by choriocarcinomas, embryonal carcinomas, polyembryomas, and in low levels by some dysgerminomas 1, 3, 4
  • Lactate dehydrogenase (LDH) serves as a marker for dysgerminoma 1, 2
  • These markers are essential for diagnosis and posttreatment surveillance when elevated at initial diagnosis 1

Sex Cord-Stromal Tumors

  • Inhibin is the primary marker for granulosa cell tumors and other sex cord-stromal tumors 1, 2
  • Surveillance includes inhibin monitoring every 2-4 months for the first 2 years, then every 6 months 1

Endometrial Cancer Markers

  • CA-125 accounts for 15% of recurrence detection in asymptomatic endometrial cancer patients 1
  • CA-125 is elevated in more than half of patients with advanced stage and/or high-grade histology 1
  • CA-125 should not be used routinely in endometrial cancer but may be appropriate in select patients with advanced disease, serous histology, or elevated pretreatment levels 1

Cervical Cancer Markers

  • SCC antigen (squamous cell carcinoma antigen) is the best studied marker for cervical squamous cell carcinomas, but is unreliable with elevation in only 28-85% of cases 5
  • Clinical utility of serum markers in cervical cancer remains very limited 3

Histologic Subtype-Specific Considerations

Mucinous Tumors

  • CEA and CA 19-9 are particularly elevated in mucinous adenocarcinomas of the endocervix and ovary 4, 6
  • Serum CEA and SP3 are raised in 52% and 43% respectively of ovarian mucinous cystadenocarcinoma patients 6

Serous Tumors

  • CA-125 and TPA (tissue polypeptide antigen) are elevated in 81% and 57% respectively of ovarian serous cystadenocarcinoma patients 6

Molecular Testing Recommendations

  • BRCA1/2 mutation testing (germline and/or somatic) is recommended at diagnosis for all patients with high-grade non-mucinous tubo-ovarian carcinoma regardless of stage 1
  • Genomic instability tests are recommended in BRCA wild-type high-grade non-mucinous FIGO stage III-IV tubo-ovarian carcinoma for first-line maintenance therapy decisions 1

Clinical Pitfalls

  • Tumor marker elevation does not equal early-stage disease detection—most markers lack sufficient sensitivity for screening 1
  • Age, menopausal status, and comorbidities must be considered when interpreting results 2
  • Markers are most useful for monitoring disease status in patients whose tumors contain high antigen concentrations, identified through immunohistochemical staining 4

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the tumor markers used for gynecological cancers?
What is the role of Carcinoembryonic Antigen (CEA) as a tumor marker in gynecology?
What cancer marker labs are recommended for a patient with various risk factors and symptoms, and how often should they be tested?
How can new Immunohistochemistry (IHC) markers improve the diagnosis and treatment of ovarian cancer?
What serum tumor markers should be ordered for a β‑hCG‑positive cancer?
What is the complete multidrug therapy regimen for treating leprosy, including dosing for paucibacillary and multibacillary disease?
What is the recommended management for a cyst located adjacent to the superior margin of the navicular bone?
In a patient with acute congestive heart failure exacerbation presenting with dyspnea and hypoxemia, should CPAP (continuous positive airway pressure) or BiPAP (bilevel positive airway pressure) be used as the initial non‑invasive ventilatory support?
What is the appropriate evaluation and management for a warm, red, swollen knee?
In a premenopausal woman using low‑dose Lo Loestrin Fe and estradiol‑testosterone vaginal cream for early atrophic vaginitis, how can I differentiate vulvovaginal candidiasis (VVC), cytolytic vaginosis (CV), and desquamative inflammatory vaginitis (DIV) based on discharge appearance, vaginal pH, and microscopic findings?
What are the current recommended treatment regimens for drug‑susceptible and multidrug‑resistant tuberculosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question